Neoadjuvant chemotherapy before cytoreductive surgery has a more detrimental prognostic impact in newly diagnosed gBRCA mutated compared to gBRCA wild-type advanced HGOSC patients undergoing PARP-inhibitor monotherapy as first-line maintenance treatment.

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Ilary Ruscito, Adriana Ionelia Apostol, Giorgia Russo, Serena Maria Boccia, Laura Vertechy, Matteo Bruno, Carolina Maria Sassu, Diana Giannarelli, Anna Fagotti, Cláudia Marchetti
DOI: 10.1016/j.ijgc.2025.103968
Cited by: 0

Fields of Study & Subjects

PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment BRCA gene mutations in cancer

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
103968–103968
Publication date
1 February 2026
Language
EN